September 2021: Algo Signal Performance Review.

Posted on | by Leon Hinde

The updated 5-year performance data for all Algo Engine buy and sell signals for the period ending 30 September.

Model Name: ASX S&P100 is 15.38% p/a.

Model Name: ASX ALL ETF is 14.85%.

Model Name: US S&P100 is 17.53% p/a.

June 2021 Data:

The updated 5-year performance data for all Algo Engine buy and sell signals for the period ending 30 June 2021

Model Name: ASX S&P100 is 14.87% p/a.

Model Name: ASX ALL ETF is 14.9%.

Model Name: US S&P100 is 19.29% p/a.

Disclaimer: This data illustrates the simulated 5 year historical time weighted rate of return of applying our algorithm based investment model over the ASX100 & US S&P100 listed securities. Past performance is no guarantee of future returns.

Neuren – Buy Signal

Posted on | by Leon Hinde

Neuren Pharmaceuticals is under Algo Engine buy conditions.

Neuren Pharmaceuticals reported the successful completion of its Share Purchase Plan (SPP) at $2.05 per share, which closed on Friday 1 October 2021. The SPP was offered to give all shareholders in Australia and New Zealand the opportunity to subscribe for additional shares at the same price as was offered to institutional and sophisticated investors in the recent placement.

Total gross proceeds of $23.3 million from the placement and SPP will accelerate the development and increase the value of NNZ-2591 for four neurodevelopmental disorders, by enabling a Phase 2 clinical trial in Prader-Willi syndrome and the foundational work for Phase 3 development across Prader-Willi, Phelan-McDermid, Angelman and Pitt Hopkins syndromes. NNZ-2591 has Orphan Drug designation from the US Food and Drug Administration for all four disorders and from the European Medicines Agency for three.

Neuren CEO Jon Pilcher commented: “We are pleased with and grateful for the support of shareholders in both the placement and the SPP. Neuren is now in a strong financial position as we approach the Rett syndrome Phase 3 results for trofinetide and advance the development of NNZ-2591 for multiple neurodevelopmental disorders in parallel.”

TWE – FY22 Earnings

Posted on | by Leon Hinde

Treasury Wine Estates is under Algo Engine buy conditions.

TWE continues to adjust to a post pandemic/post Chinese tariff environment. FY21 EBIT of $510 exceeded market expectations. After a number of years of disappointment for TWE in this region, we see America’s division accelerating growth into FY22.

FY22 EBIT growth is forecast to be in the mid to high single-digit range.

ASX 200 Resources Fund

Posted on | by Leon Hinde

OZR:ASX is under Algo Engine buy conditions and we anticipate buying support to increase within the accumulation range of $10.50 to $12.50.

A sector sub-index of the S&P/ASX 200 Index, this index provides investors with exposure to the Resources sector of the Australian equity market as classified as members of the GICS® resources sector. Resources are defined as companies classified in the Energy sector (GICS® Tier 1), as well as companies classified in the Metals and Mining Industry (GICS® Tier 3).